113525-87-4

Usage

Uses

Used in Pharmaceutical Industry:
Ibufenac is utilized as an analgesic and anti-inflammatory agent for the treatment of conditions such as arthritis, menstrual pain, and acute injuries. Its ability to inhibit prostaglandin production helps in reducing pain and inflammation associated with these conditions.
However, it is important to note that ibufenac is not as widely used as ibuprofen due to its limited availability and potential for side effects. Further research and development may be necessary to enhance its accessibility and safety profile for broader use in the pharmaceutical industry.

Upstream product

• 113525-78-3 methyl N-Boc-2-oxazolidinone-5-carboxylate 
• 218916-64-4 3-tert-butyloxycarbonylamino-2(RS)-hydroxypropionic acid 
• 74-88-4 methyl iodide 
• 24424-99-5 di-tert-butyl dicarbonate 
• 147851-98-7 methyl 3-amino-2-hydroxypropionate 

Relevant academic research and scientific papers

NOVEL COMPOUNDS AND THEIR USE

The present invention provides compounds of the general formula (I) or a pharmaceutically acceptable prodrugs, salts and/or solvates thereof, wherein LHS is selected from the group consisting of LHSa and LHSb And wherein, the asterisk (*) marks the point of attachment; These compounds exhibit antibacterial activity against Gram-negative and Gram-positive bacteria, especially S. aureus, E. coli, K. pneumoniae and A. baumannii. Pharmaceutical compositions containing these compounds, therapeutic uses thereof and methods for manufacturing the same are also provided.

NON-FUSED TRICYCLIC COMPOUNDS

Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for treating cancers. Specific cancers include those that are mediated by YAP/TAZ or those that are modulated by the interaction between YAP/TAZ and TEAD.

GLYCOSAMINOGLYCAN DERIVATIVE AND METHOD FOR PRODUCING SAME

The present invention provides a glycosaminoglycan derivative in which a group derived from glycosaminoglycan and a group derived from a physiologically active substance having at least one of a carboxy group and a hydroxy group are coupled by covalent bond with a spacer therebetween, in which the spacer is selected in accordance with the decomposition rate of the covalent bond to the group derived from the physiologically active substance.

1,3,4-OXADIAZOLE AND 1,3,4-THIADIAZOLE BETA-LACTAMASE INHIBITORS

β-Lactamase inhibitor compounds (BLIs) are disclosed, including compounds that have activity against class A, class C or class D β-lactamases. Methods of manufacturing the BLIs, and uses of the compounds in the preparation of pharmaceutical compositions and antibacterial applications are also disclosed.

MILD AND SELECTIVE RING-CLEAVAGE OF CYCLIC CARBAMATES TO AMINO ALCOHOLS

N-tert-Butoxycarbonylated 2-oxazolidinones and tetrahydro-2-oxazinones are smoothly cleaved to acyclic N-Boc-amino alcohols on treatment with catalytic amounts of cesium carbonate at room temperature.The versatility of the procedure is demonstrated in a facile cleavage of highly functionalized heterocycles without epimerization and β-elimination.